Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, COO & Managing Director E | July 05, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date July 05, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 14,663 |
Ending reported balance
After 2022-07-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-07-05 · Exercise / conversion · Acquired 4,032 · Balance 19,872 Row 2 · 2022-07-05 · Sale · Disposed 4,032 · Balance 15,840 Row 3 · 2022-07-05 · Sale · Disposed 1,177 · Balance 14,663 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2031-02-22 | Direct | 4,031 |
Reported balance
After 2022-07-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-05 · Exercise / conversion · Disposed 4,032 · Balance 4,031 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 2,496 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.81 · Expires 2027-01-06 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 52,560 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-01-06 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 6,468 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 58,884 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2028-02-26 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 119,340 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2028-02-26 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 17,904 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-05 · Disposition to issuer · Disposed 42,048 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-05 · Disposition to issuer · Disposed 79,812 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-05 · Disposition to issuer · Disposed 17,964 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-05 · Disposition to issuer · Disposed 137,016 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-05 · Disposition to issuer · Disposed 82,224 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-02-22 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-05 · Disposition to issuer · Disposed 67,440 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-02-22 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-05-05 · Disposition to issuer · Disposed 42,192 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2022 Filed Jul 7, 2022 21:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001765581-22-000069 · edgardoc.xml · derivative · entry 4 Tovey Christopher J. · CIK 0001754163 · EVP, COO & Managing Director E 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,031 Underlying: Ordinary Shares · 4,032 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,177 | $160.00 | $188,320.00 |
DisclosureSEC source: 0001765581-22-000069 · edgardoc.xml · nonDerivative · entry 3 Tovey Christopher J. · CIK 0001754163 · EVP, COO & Managing Director E 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,663 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 4,032 | $160.00 | $645,120.00 |
DisclosureSEC source: 0001765581-22-000069 · edgardoc.xml · nonDerivative · entry 2 Tovey Christopher J. · CIK 0001754163 · EVP, COO & Managing Director E 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,840 Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,032 | $0.02 | $80.64 |
DisclosureSEC source: 0001765581-22-000069 · edgardoc.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · EVP, COO & Managing Director E 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2022 Filed May 10, 2022 01:46 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,096 | $153.22 | $167,929.12 |
DisclosureSEC source: 0001765581-22-000043 · edgardoc.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · EVP, COO & Managing Director E 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,840 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 23:08 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 7,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000032 · edgardoc.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,936 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 42,192 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 13 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 42,192 shares Expires 2031-02-22 F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 67,440 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 12 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 67,440 shares Expires 2031-02-22 F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 82,224 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 11 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 82,224 shares Expires 2030-06-04 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 137,016 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 10 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 137,016 shares Expires 2030-06-04 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 17,964 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 9 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,964 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 79,812 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 8 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 79,812 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 42,048 | Not disclosed Strike: $14.33 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 7 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 42,048 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 17,904 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 6 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,904 shares Expires 2028-02-26 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 119,340 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 5 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 119,340 shares Expires 2028-02-26 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 58,884 | Not disclosed Strike: $9.61 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 4 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 58,884 shares Expires 2028-02-26 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 6,468 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 3 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,468 shares Expires 2027-01-06 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 52,560 | Not disclosed Strike: $9.81 | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · derivative · entry 2 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 52,560 shares Expires 2027-01-06 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:25 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerOrdinary Shares | 2,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018673 · doc4.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:46 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 9,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000057 · edgardoc.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · EVP COO & Managing Dir EUR/INT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,116 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of May 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:44 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 42,192 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008084 · doc4.xml · derivative · entry 2 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,192 Underlying: Ordinary Shares · 42,192 shares Expires 2031-02-22 F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 18:44 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 67,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008084 · doc4.xml · derivative · entry 1 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,440 Underlying: Ordinary Shares · 67,440 shares Expires 2031-02-22 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest on February 22, 2024 if certain performance conditions are satisfied. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 28,560 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · derivative · entry 17 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 28,560 shares Expires 2027-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.34 U.S. Dollars as of December 1, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 9,060 | $11.79 | $106,817.40 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 10 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,496 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F4 · shares: Represented by ADSs. F8 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($141.5258 per ADS). These shares were sold in multiple transactions at prices ranging from $141.40 per ADS (or $11.78 per ordinary share) to $142.00 per ADS (or $11.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 19,500 | $11.74 | $228,930.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 9 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,556 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F4 · shares: Represented by ADSs. F7 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.8760 per ADS). These shares were sold in multiple transactions at prices ranging from $140.40 per ADS (or $11.78 per ordinary share) to $141.31 per ADS (or $11.78 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 28,560 | $0.00 | $37.13 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 8 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F6 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.34 U.S. Dollars as of December 1, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 5,988 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · derivative · entry 16 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,988 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 8,952 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · derivative · entry 15 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,952 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 57,684 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · derivative · entry 14 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,560 Underlying: Ordinary Shares · 57,684 shares Expires 2027-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 6,468 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · derivative · entry 13 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,468 shares Expires 2027-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 10,452 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · derivative · entry 12 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5 Underlying: Ordinary Shares · 10,452 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 3,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · derivative · entry 11 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6 Underlying: Ordinary Shares · 3,924 shares Expires 2025-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 93,468 | $11.67 | $1,090,771.56 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 7 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,496 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F4 · shares: Represented by ADSs. F5 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.0338 per ADS). These shares were sold in multiple transactions at prices ranging from $140.00 per ADS (or $11.66 per ordinary share) to $140.25 per ADS (or $11.69 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 5,988 | $0.00 | $7.78 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 6 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 8,952 | $0.00 | $11.64 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 5 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 57,684 | $0.00 | $74.99 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 4 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 6,468 | $0.00 | $8.41 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 3 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 10,452 | $0.00 | $13.59 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 2 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 3,924 | $0.00 | $5.10 |
DisclosureSEC source: 0000899243-20-032605 · doc4.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020. F9 · balance_after: Reflects an adjustment to total holdings to exclude seven shares incorrectly included in prior reports. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 82,224 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015694 · doc4.xml · derivative · entry 2 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,224 Underlying: Ordinary Shares · 82,224 shares Expires 2030-06-04 F2 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on June 4, 2021. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 137,016 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015694 · doc4.xml · derivative · entry 1 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,016 Underlying: Ordinary Shares · 137,016 shares Expires 2030-06-04 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest on June 4, 2023 if certain performance conditions are satisfied. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest on June 4, 2023 if certain performance conditions are satisfied. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 64,800 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0000899243-19-015678 · doc4.xml · derivative · entry 3 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 64,800 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 3, 2019. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 64,800 | $14.61 | $946,728.00 |
DisclosureSEC source: 0000899243-19-015678 · doc4.xml · nonDerivative · entry 2 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,503 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2019. F4 · price: The price reported in Column 4 is a weighted average price per ordinary share ($175.35 per ADS). These shares were sold in multiple transactions at prices ranging from $175.04 per ADS (or $14.59 per ordinary share) to $175.64 per ADS (or $14.64 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 64,800 | $3.24 | $209,952.00 |
DisclosureSEC source: 0000899243-19-015678 · doc4.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 3, 2019. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 1,200 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-19-014050 · doc4.xml · derivative · entry 3 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,800 Underlying: Ordinary Shares · 1,200 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of May 15, 2019. F5 · balance_after: The balance has been reduced to adjust for an overstatement of 1,000 shares in the reporting person's form 4 filed on May 9, 2019. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 1,200 | $15.01 | $18,012.00 |
DisclosureSEC source: 0000899243-19-014050 · doc4.xml · nonDerivative · entry 2 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,503 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019. F4 · price: The exercise price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 1,200 | $3.29 | $3,948.00 |
DisclosureSEC source: 0000899243-19-014050 · doc4.xml · nonDerivative · entry 1 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of May 15, 2019. Read SEC document |
| May 07, 2019 Filed May 9, 2019 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 8,952 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-012933 · doc4.xml · derivative · entry 9 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,952 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019. Read SEC document |
| May 07, 2019 Filed May 9, 2019 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 6,468 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-012933 · doc4.xml · derivative · entry 8 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,468 shares Expires 2027-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019. Read SEC document |
| May 07, 2019 Filed May 9, 2019 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 7,508 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-012933 · doc4.xml · derivative · entry 7 Tovey Christopher J. · CIK 0001754163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Ordinary Shares · 7,508 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.